Capricor Therapeutics, Inc.

NasdaqCM CAPR

Capricor Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 95.71%

Capricor Therapeutics, Inc. Gross Profit Margin is 95.71% for the Trailing 12 Months (TTM) ending September 30, 2024, a 136.87% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Capricor Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 40.41%, a -59.49% change year over year.
Capricor Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 99.76%, a 103.25% change year over year.
Capricor Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -3,072.29%, a -140.33% change year over year.
Capricor Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -1,278.37%, a -219.18% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: CAPR

Capricor Therapeutics, Inc.

CEO	Dr. Linda Marbán Ph.D.
IPO Date	Feb. 13, 2007
Location	United States
Headquarters	10865 Road to the Cure
Employees	101
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Key trends

Past 5 years